Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers.

Literature DB >> 30215054

Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers.

Nishant Mohan¹, Jiangsong Jiang¹, Milos Dokmanovic¹, Wen Jin Wu¹.

Abstract

Trastuzumab, an epidermal growth factor receptor 2 (HER2) targeting humanized monoclonal antibody, has been approved for the treatment HER2-positive breast cancer and HER2-positve metastatic gastric cancer. However, cardiotoxicity associated with its clinical application poses challenges for clinicians and patients, mechanisms of which are still evolving. This review will summarize the current mechanistic understanding of trastuzumab-mediated cardiotoxicity, discuss the novel role of DNA topoisomerase IIB as a shared target for enhanced cardiotoxicity induced by trastuzumab and anthracyclines-based combination regimens, and speculate the potential impact of trastuzumab intervention in immune checkpoint inhibitors-based therapies.

Entities: Chemical Disease Gene Species

Keywords: HER2; TOP2B; cardiotoxicity; trastuzumab

Year: 2018 PMID： 30215054 PMCID： PMC6131716 DOI： 10.1093/abt/tby003

Source DB: PubMed Journal: Antib Ther

32 in total

Review 1. Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter.

Authors: Chau T Dang; Anthony F Yu; Lee W Jones; Jennifer Liu; Richard M Steingart; Daniel F Argolo; Larry Norton; Clifford A Hudis
Journal: J Clin Oncol Date: 2016-02-01 Impact factor: 44.544

2. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.

Authors: David Cameron; Martine J Piccart-Gebhart; Richard D Gelber; Marion Procter; Aron Goldhirsch; Evandro de Azambuja; Gilberto Castro; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Nedal Al-Sakaff; Sabine Lauer; Eleanor McFadden; Brian Leyland-Jones; Richard Bell; Mitch Dowsett; Christian Jackisch
Journal: Lancet Date: 2017-02-17 Impact factor: 79.321

3. Phase I and II clinical trials of trastuzumab.

Authors: J Baselga
Journal: Ann Oncol Date: 2001 Impact factor: 32.976

4. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.

Authors: J Baselga; D Tripathy; J Mendelsohn; S Baughman; C C Benz; L Dantis; N T Sklarin; A D Seidman; C A Hudis; J Moore; P P Rosen; T Twaddell; I C Henderson; L Norton
Journal: Semin Oncol Date: 1999-08 Impact factor: 4.929

Review 5. Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.

Authors: Milos Dokmanovic; Kathryn E King; Nishant Mohan; Yukinori Endo; Wen Jin Wu
Journal: Expert Opin Drug Metab Toxicol Date: 2017-06-09 Impact factor: 4.481

6. Adjuvant trastuzumab in HER2-positive breast cancer.

Authors: Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal: N Engl J Med Date: 2011-10-06 Impact factor: 91.245

7. Identification of the molecular basis of doxorubicin-induced cardiotoxicity.

Authors: Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh
Journal: Nat Med Date: 2012-10-28 Impact factor: 53.440

8. Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice.

Authors: M Khair ElZarrad; Partha Mukhopadhyay; Nishant Mohan; Enkui Hao; Milos Dokmanovic; Dianne S Hirsch; Yi Shen; Pal Pacher; Wen Jin Wu
Journal: PLoS One Date: 2013-11-08 Impact factor: 3.240

9. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.

Authors: Erin J Aiello Bowles; Robert Wellman; Heather Spencer Feigelson; Adedayo A Onitilo; Andrew N Freedman; Thomas Delate; Larry A Allen; Larissa Nekhlyudov; Katrina A B Goddard; Robert L Davis; Laurel A Habel; Marianne Ulcickas Yood; Catherine McCarty; David J Magid; Edward H Wagner
Journal: J Natl Cancer Inst Date: 2012-09-05 Impact factor: 13.506

Review 10. Cardiotoxicity of immune checkpoint inhibitors.

Authors: Gilda Varricchi; Maria Rosaria Galdiero; Giancarlo Marone; Gjada Criscuolo; Maria Triassi; Domenico Bonaduce; Gianni Marone; Carlo Gabriele Tocchetti
Journal: ESMO Open Date: 2017-10-26

35 in total

1. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.

Authors: Helena Earl; Louise Hiller; Anne-Laure Vallier; Shrushma Loi; Karen McAdam; Luke Hughes-Davies; Daniel Rea; Donna Howe; Kerry Raynes; Helen B Higgins; Maggie Wilcox; Chris Plummer; Betania Mahler-Araujo; Elena Provenzano; Anita Chhabra; Sophie Gasson; Claire Balmer; Jean E Abraham; Carlos Caldas; Peter Hall; Bethany Shinkins; Christopher McCabe; Claire Hulme; David Miles; Andrew M Wardley; David A Cameron; Janet A Dunn
Journal: Health Technol Assess Date: 2020-08 Impact factor: 4.014

Review 2. Human In Vitro Models for Assessing the Genomic Basis of Chemotherapy-Induced Cardiovascular Toxicity.

Authors: Emily A Pinheiro; Tarek Magdy; Paul W Burridge
Journal: J Cardiovasc Transl Res Date: 2020-02-20 Impact factor: 4.132

Review 3. Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer.

Authors: Giuseppe Curigliano; Evandro de Azambuja; Daniel Lenihan; Maria Grazia Calabrò; Daniela Cardinale; Carlo Maria Cipolla
Journal: Oncologist Date: 2019-05-07

4. Protective Effect of Curcumin, Chrysin and Thymoquinone Injection on Trastuzumab-Induced Cardiotoxicity via Mitochondrial Protection.

Authors: Leila Rezaie Shirmard; Mohammad Shabani; Amin Ashena Moghadam; Nasim Zamani; Hadi Ghanbari; Ahmad Salimi
Journal: Cardiovasc Toxicol Date: 2022-05-14 Impact factor: 3.231

Review 5. Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity.

Authors: Juan Tamargo; Ricardo Caballero; Eva Delpón
Journal: Drug Saf Date: 2022-01-13 Impact factor: 5.606

6. Incidence of trastuzumab-induced cardiotoxicity and impact of body mass index in patients with breast cancer: Results from a Saudi tertiary cancer center.

Authors: Khalid Al-Saleh; Ahmed Abdel-Warith; Mohammed Alghamdi; Abdurrahman Aldiab; Arwa Ali; Eyad Fawzi Alsaeed; Waleed Nabeel Abozeed; Nashwa Abdel-Aziz
Journal: Mol Clin Oncol Date: 2022-02-08

7. Myocardial perfusion years after radiation therapy for left-sided breast cancer: Normal or abnormal? This is the question.

Authors: Alberto Aimo; Alessia Gimelli
Journal: J Nucl Cardiol Date: 2019-11-19 Impact factor: 5.952